序号 |
标题 |
次数 |
作者 |
发布时间 |
74611 |
Mal-PEG1-Val-Cit-OH,马来酰亚胺-一聚乙二醇-VAL-CIT-羟基 |
86 |
WYQ |
2024-12-19 |
74612 |
cas:1342820-51-2,SGD-1910, ADC试剂 |
108 |
kx |
2024-12-19 |
74613 |
Ald-Ph-amido-PEG2-C2-Pfp ester CAS:2101206-60-2 |
92 |
zyl |
2024-12-19 |
74614 |
cas:1228105-52-9,DM4-SMCC, ADC试剂 |
100 |
kx |
2024-12-19 |
74615 |
马来酰亚胺-八聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP酯,ADC定制 |
90 |
wyh |
2024-12-19 |
74616 |
cas:863971-56-6,Val-Cit-PAB-MMAF, ADC试剂 |
68 |
kx |
2024-12-19 |
74617 |
SPDMB CAS:2101206-29-3合成方法 |
86 |
zyl |
2024-12-19 |
74618 |
cas:2055041-39-7,Mal-PEG4-Val-Cit-PAB-OH,ADC定制 |
82 |
wyh |
2024-12-19 |
74619 |
cas:1347750-81-5,Mal-NH-PEG2-CH2CH2COOPFP ester, ADC试剂 |
78 |
kx |
2024-12-19 |
74620 |
金属螯合剂DOTA偶联α-MSH八肽类似物 |
64 |
h |
2024-12-19 |
74621 |
cas:1286715-33-0,2,5-Dioxopyrrolidin-1-yl 4-methyl-4-((2-methyl-5-oxo-5-(2-(trimethylsilyl)ethoxy)pentan-2-yl)disulfanyl)pentanoate |
101 |
kx |
2024-12-19 |
74622 |
DOTA-conjugated multivalent cyclic-RGD DOTA-共轭多价环RGD肽树枝状大分子 |
69 |
h |
2024-12-19 |
74623 |
Azidoethyl-SS-ethylazide CAS:352305-38-5 |
78 |
zyl |
2024-12-19 |
74624 |
CAS: 870487-09-5, Boc-Val-Cit-PAB |
78 |
WYQ |
2024-12-19 |
74625 |
cas:2101206-67-9,Ald-Ph-amido-PEG1-C2-Pfp ester, ADC试剂 |
71 |
kx |
2024-12-19 |
74626 |
Ald-Ph-amido-PEG11-NH-Boc CAS:1245813-70-0 |
94 |
zyl |
2024-12-19 |
74627 |
HSA-2-iminothiolane-DOTA HSA-2-亚氨基硫醇-DOTA |
90 |
h |
2024-12-19 |
74628 |
cas:1222787-24-7,2,5-Dioxopyrrolidin-1-yl 4-((2-((2-(2-(4-(2,6-dioxo-1,3-dipropyl-2,3,6,9-tetrahydro-1H-purin-8-yl)phenoxy)acetamido)ethyl)amino)ethyl)disulfanyl)-4-oxobutanoate |
201 |
kx |
2024-12-19 |
74629 |
Tr-PEG5-OH CAS:141282-24-8物理化学性质 |
96 |
zyl |
2024-12-19 |
74630 |
CAS: 870487-08-4,Boc-Val-Cit,(S)-2-((S)-2-((叔丁氧基羰基)氨基)-3-甲基丁酰胺基)-5-脲基戊酸 |
96 |
WYQ |
2024-12-19 |
74631 |
DOTA-8-Aoc-BBN[7-14]NH |
102 |
h |
2024-12-19 |
74632 |
Fmoc-PEG3-Val-Cit,N-Fluorenylmethoxycarbonyl-triethylene glycol-Val-Cit |
81 |
WYQ |
2024-12-19 |
74633 |
CAS: 2226472-28-0,DBCO-PEG4-Val-Cit-PAB-PNP |
78 |
WYQ |
2024-12-19 |
74634 |
CAS: 2055024-64-9,Azido-PEG4-Val-Cit-PAB-OH |
82 |
WYQ |
2024-12-19 |
74635 |
CAS: 870487-09-5,Boc-Val-Cit-PAB |
84 |
WYQ |
2024-12-19 |
74636 |
CAS:784105-33-5 Amino-PEG3-C2-acid的介绍 |
72 |
zyl |
2024-12-19 |
74637 |
CAS 863971-53-3:Fmoc-Val-Cit-PAB-PNP |
87 |
WYQ |
2024-12-19 |
74638 |
Ald-Ph-amido-PEG11-C2-NH2 CAS:1337889-01-6 |
69 |
zyl |
2024-12-19 |
74639 |
cas:2003260-13-5 , MA-PEG4-Ala-Ala-PAB-PNP,ADC定制 |
73 |
wyh |
2024-12-19 |
74640 |
DOTA-NCS-6-Ahx-Phe 19-ST[1-19] DOTA偶联ST肽类似物 |
102 |
h |
2024-12-19 |
74641 |
1,4,7,10-四氮杂-n-(1-羧基-3-(4-硝基苯基)丙基)-n,N , N ‴-tris(acetic酸)环十二烷(PA-DOTA) |
67 |
h |
2024-12-19 |
74642 |
CAS 159858-22-7:Fmoc-Val-Cit-PAB-OH |
61 |
WYQ |
2024-12-19 |
74643 |
cas:5117-19-1,Octanethyl glycol ,八乙二醇的主要特点 |
97 |
zyl |
2024-12-19 |
74644 |
CAS 159857-79-1:Val-Cit-PAB-OH,缬氨酸(Val)、琥珀酰亚胺(Cit)和对氨基苯甲酸(PAB)的衍生物 |
106 |
WYQ |
2024-12-19 |
74645 |
SPDP-Val-Cit-PAB-OH,ADC定制 |
67 |
wyh |
2024-12-19 |
74646 |
DOTA-LVT 螯合剂DOTA偶联Lys8-血管收缩素 |
97 |
h |
2024-12-19 |
74647 |
cas:2054345-67-2,azido-tris(ethylenoxy)-L-alanine TFA Salt化学性质 |
83 |
zyl |
2024-12-19 |
74648 |
cas:68617-64-1,SPDP acid,3-(2-吡啶二硫代)丙酸的合成方法 |
119 |
zyl |
2024-12-19 |
74649 |
1,4,7,10-四(羧甲基)-1,4,7,10-四氮杂环十二烷单酰胺偶联葡萄糖 |
84 |
h |
2024-12-19 |
74650 |
PEG-P(Asp-Gd-DOTA)Gd‐DOTA偶联聚乙二醇改性聚天冬氨酸 |
89 |
h |
2024-12-19 |
74651 |
cas:70539-42-3,EGS Crosslinker,乙二醇-双(琥珀酸N-羟基琥珀酰亚胺酯)的结构式 |
140 |
zyl |
2024-12-19 |
74652 |
CXCR4导向的五肽[(68)Ga]喷替沙福(环(-D-Tyr-N-Me-D-Orn(AMB-DOTA)-L-Arg-L-2-Nal-Gly-)) |
119 |
h |
2024-12-19 |
74653 |
α-hexadecyl-DOTA α-十六烷基-DOTA |
83 |
h |
2024-12-19 |
74654 |
Methyltetrazine-SS-NHS 甲基四唑-双硫键-活性酯的合成方法 |
75 |
zyl |
2024-12-19 |
74655 |
DOTA-AgRP-6E |
110 |
h |
2024-12-19 |